ZOE Stock Overview
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$141.00 |
| 52 Week High | US$185.00 |
| 52 Week Low | US$135.28 |
| Beta | 0.85 |
| 1 Month Change | -7.11% |
| 3 Month Change | -19.84% |
| 1 Year Change | -10.56% |
| 3 Year Change | -1.40% |
| 5 Year Change | 55.03% |
| Change since IPO | 471.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZOE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.4% | 3.2% | 1.7% |
| 1Y | -10.6% | -28.2% | 2.3% |
Return vs Industry: ZOE exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: ZOE underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| ZOE volatility | |
|---|---|
| ZOE Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ZOE's share price has been volatile over the past 3 months.
Volatility Over Time: ZOE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 14,100 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
Zoetis Inc. Fundamentals Summary
| ZOE fundamental statistics | |
|---|---|
| Market cap | €64.38b |
| Earnings (TTM) | €2.19b |
| Revenue (TTM) | €7.98b |
29.4x
P/E Ratio8.1x
P/S RatioIs ZOE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZOE income statement (TTM) | |
|---|---|
| Revenue | US$8.54b |
| Cost of Revenue | US$2.56b |
| Gross Profit | US$5.99b |
| Other Expenses | US$3.64b |
| Earnings | US$2.34b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 5.13 |
| Gross Margin | 70.06% |
| Net Profit Margin | 27.43% |
| Debt/Equity Ratio | 132.1% |
How did ZOE perform over the long term?
See historical performance and comparison